Randomized, Phase 3, Placebo-Controlled Double-Blind, Multicenter Trial of a One Time Intracoronary Administration of Ad5.hAC6 Gene Transfer for Patients With Reduced Left Ventricular Heart Failure
Latest Information Update: 05 Nov 2021
At a glance
- Drugs RT 100 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms FLOURISH
- Sponsors Renova Therapeutics
- 05 Jun 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Dec 2018 Planned End Date changed from 1 Sep 2022 to 1 Jun 2023.
- 15 Dec 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Jun 2020.